Group 4 Created with Sketch.
Your changes have been saved

David R. Jones, MD - Turning Tides in Targeted Therapy for Early-Stage EGFR-Mutated NSCLC: Latest Data and Practical Guidance for Thoracic Surgeons and the Multidisciplinary Team on the Emerging Role of EGFR-Targeted Therapy in Resectable Lung Cancer

Share
station description Thought leader perspectives on current clinical advances in medicine.
PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast
Duration: 57:44
Go online to PeerView.com/ZUJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In the era of precision medicine, genomic profiling to individualize management of patients with advanced non–small cell lung cancer (NSCLC) is paramount. Advances in
Snippets are a new way to share audio!
You can clip a small part of any file to share, add to playlist, and transcribe automatically. Just click the to create your snippet!
Snippets: Clips of David R. Jones, MD - Turning Tides in Targeted Therapy for Early-Stage EGFR-Mutated NSCLC: Latest Data and Practical Guidance for Thoracic Surgeons and the Multidisciplinary Team on the Emerging Role of EGFR-Targeted Therapy in Resectable Lung Cancer that people like
There are currently no snippets from David R. Jones, MD - Turning Tides in Targeted Therapy for Early-Stage EGFR-Mutated NSCLC: Latest Data and Practical Guidance for Thoracic Surgeons and the Multidisciplinary Team on the Emerging Role of EGFR-Targeted Therapy in Resectable Lung Cancer.
Snippets are an easy way to highlight your favorite soundbite from any piece of audio and share with friends, or make a trailer for PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast
Playlists that David R. Jones, MD - Turning Tides in Targeted Therapy for Early-Stage EGFR-Mutated NSCLC: Latest Data and Practical Guidance for Thoracic Surgeons and the Multidisciplinary Team on the Emerging Role of EGFR-Targeted Therapy in Resectable Lung Cancer appears on.
There are currently no playlists containing this audio.
Add this audio track to one of your playlists
Add to Playlist
Up Next
Full Description
Back to Top
Go online to PeerView.com/ZUJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In the era of precision medicine, genomic profiling to individualize management of patients with advanced non–small cell lung cancer (NSCLC) is paramount. Advances in targeted therapy in advanced/metastatic NSCLC have heightened interest in expanding its use into earlier stages of the disease to improve outcomes in curative intent settings. Subsequently, a growing body of evidence now supports the use of EGFR-targeted therapy in early-stage disease, with remarkable efficacy results in the adjuvant setting. Results from ongoing studies of neoadjuvant and adjuvant targeted therapy are eagerly awaited as well. Given that targeted therapy is becoming an increasingly useful tool in early-stage NSCLC, it is essential that thoracic surgeons and other members of the multidisciplinary lung cancer team remain current with the latest clinical trial data and practical implications of incorporating systemic therapy into multimodal management strategies. This web broadcast provides the most important information required to effectively navigate the increasingly complex evidence base of EGFR-targeted therapy, focusing on the nuances of molecular testing and targeted treatment in the context of patient-centered, multidisciplinary management of EGFR-mutant NSCLC. Upon completion of this activity, participants should be better able to: Characterize the molecular heterogeneity of NSCLC and the oncogenic drivers such as EGFR mutations that serve as therapeutic targets and help to inform treatment decisions regarding targeted therapies, Describe the latest safety and efficacy data on neoadjuvant/adjuvant EGFR-targeted therapies in patients with early-stage EGFR-mutated NSCLC, Discuss evolving evidence and best practices for EGFR testing in lung cancer, including in early-stage NSCLC, and the thoracic surgeon’s role in optimizing sample collection and evaluation, Collaborate with the multidisciplinary team to safely integrate neoadjuvant/adjuvant EGFR-targeted therapies into multimodal treatment plans for eligible patients with early-stage NSCLC in the context of clinical practice or clinical trials, according to recent evidence, precision oncology principles, and patient values and preferences.
Up Next
Add to playlist
New playlist

Embed

COPY
Embed Options
Create Playlist
Select the Station you want to upload this audio to
Station
0 / 140
0 / 2000
Playlist Icon Image:
(.jpg, .png, min size 500x500px)
Privacy
Subscribers
Your
voice
matters.
Discover & Listen to the world’s largest free collection of audio
Password reset

Enter your email address that you used to register. We'll send you an email with your username and a link to reset your password.



If you still need help, contact Vurbl Support
Password reset sent

You have been sent instructions on resetting you password to the email associated with your account. Please check your email and signing in again.


Back to Sign In
If you still need help, contact Vurbl Support
Your
voice
matters.
Discover & Listen to the world’s largest free collection of audio
Reset password

Please enter your new password below.



If you still need help, contact Vurbl Support
Your voice matters.
Discover & Listen to the world’s largest free collection of audio
Verify Email

Enter your email address that you used to register. We'll send you an email with a link to verify your email.



Cancel
Delete Profile
Are you sure? We will miss you :'(
Delete
Delete Audio
Are you sure?
Delete
Delete Playlist
Are you sure you want to delete this playlist?
Delete
Notifications Mark all as read
    You currently have no notifications
    Edit Snippet
    0 / 140
    0 / 140